{
    "name": "fluoroestradiol F 18",
    "comment": "Rx",
    "other_names": [
        "Cerianna"
    ],
    "classes": [
        "Diagnostic Imaging Agents"
    ],
    "source": "https://reference.medscape.com/drug/cerianna-fluoroestradiol-f-18-4000115",
    "pregnancy": {
        "common": [
            "All radiopharmaceuticals have potential to cause fetal harm depending on fetal stage of development and the magnitude of radiation dose",
            "Advise pregnant females of the potential risks of fetal exposure to radiation from administration",
            "There are no available data on use during pregnancy",
            "No animal reproduction studies have been conducted"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "There are no data on the presence of fluoroestradiol F 18 in human milk, or its effects on breastfed infants or milk production",
            "Lactation studies have not been conducted in animals",
            "Advise breastfeeding females to avoid breastfeeding for 4 hr after administration"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [],
            "specific": [
                {
                    "type": "Radiation risks",
                    "description": [
                        "Diagnostic radiopharmaceuticals expose patients to radiation",
                        "Radiation exposure is associated with a dose-dependent increased risk of cancer",
                        "Ensure safe drug handling and patient preparation procedures to protect patients and healthcare providers from unintentional radiation exposure"
                    ]
                },
                {
                    "type": "Misdiagnosis risks",
                    "description": [
                        "Inadequate tumor characterization and other ER+ pathology",
                        "Breast cancer may be heterogeneous within patients and across time",
                        "Fluoroestradiol F 18 images ER and is not useful for imaging other receptors (eg, HER2, PR)",
                        "Uptake is not specific for breast cancer and may occur in a variety of ER+ tumors that arise outside of the breast, including uterus and ovaries",
                        "Do not use in lieu of biopsy when biopsy is indicated in patients with recurrent or metastatic breast cancer",
                        "False-negative scan",
                        "A negative scan does not rule out ER+ breast cancer",
                        "Pathology or clinical characteristics that suggest a patient may benefit from systemic hormone therapy should take precedence over a discordant negative scan"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Certain classes of systemic endocrine therapies, including ER modulators and ER down-regulators, block ER, reduce the uptake of fluoroestradiol F 18, and may reduce detection of ER+ lesions after administration",
                        "Drugs from these classes (eg, tamoxifen, fulvestrant) may block ER for up to 8-28 weeks, respectively",
                        "Do not delay indicated therapy in order to administer fluoroestradiol F 18",
                        "Administer fluoroestradiol F 18 before starting systemic endocrine therapies that block ER"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "General disorders",
            "percent": null
        },
        {
            "name": "Injection",
            "percent": null
        },
        {
            "name": "site pain",
            "percent": null
        },
        {
            "name": "Neurological and gastrointestinal disorders",
            "percent": null
        },
        {
            "name": "Dysgeusia",
            "percent": null
        }
    ]
}